There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.
Research suggested that EBV is the primary cause of MS. What are the clinical implications, and could this transform treatment and prevention of this neurodegenerative condition?
Early initiation of HET in pediatric-onset MS was linked to slower progression to disability compared to treatment with low-efficacy therapy or no treatment.
Two classes of pervasive environmental chemicals that are present in household cleaners, furniture and electronics had "surprising" effects specifically on the non-nerve cells in the brain.